March 15, 2024 –VLF whole-body scanner installation in Aberdeen –
As part of the gb-spiro3d protocol, we welcomed patients with asthma and COPD. The inclusion of patients with asthma and COPD is crucial, as our aim is to study the sensitivity of 3D MR spirometry to respiratory pathologies. On 4 July 2023, the first COPD subject was included in the protocol. This was followed by an asthmatic subject on 18 July 2023 before biotherapy, who returned on 6 February 2024 after his biotherapy. This is very good news for the V|LF-Spiro3D project, as the study of these key patients should provide us with information on the respiratory behaviour of the various pathologies.